Cytokinetics (CYTK) Total Non-Current Liabilities (2016 - 2024)
Historic Total Non-Current Liabilities for Cytokinetics (CYTK) over the last 9 years, with Q3 2024 value amounting to $1.4 billion.
- Cytokinetics' Total Non-Current Liabilities rose 2298.24% to $1.4 billion in Q3 2024 from the same period last year, while for Sep 2024 it was $1.4 billion, marking a year-over-year increase of 2298.24%. This contributed to the annual value of $1.2 billion for FY2023, which is 791.9% up from last year.
- As of Q3 2024, Cytokinetics' Total Non-Current Liabilities stood at $1.4 billion, which was up 2298.24% from $1.4 billion recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Total Non-Current Liabilities registered a high of $1.4 billion during Q3 2024, and its lowest value of $153.3 million during Q1 2020.
- For the 5-year period, Cytokinetics' Total Non-Current Liabilities averaged around $784.4 million, with its median value being $736.8 million (2022).
- As far as peak fluctuations go, Cytokinetics' Total Non-Current Liabilities surged by 17016.09% in 2022, and later skyrocketed by 771.4% in 2024.
- Over the past 5 years, Cytokinetics' Total Non-Current Liabilities (Quarter) stood at $420.4 million in 2020, then surged by 41.05% to $593.0 million in 2021, then skyrocketed by 89.15% to $1.1 billion in 2022, then grew by 7.92% to $1.2 billion in 2023, then rose by 19.79% to $1.4 billion in 2024.
- Its Total Non-Current Liabilities stands at $1.4 billion for Q3 2024, versus $1.4 billion for Q2 2024 and $1.2 billion for Q1 2024.